{
  "schemaVersion": 1,
  "organisationId": "O-ea398d10efc5476aa0b769fe7e240356",
  "slug": "legend-biotech-corp",
  "name": "Legend Biotech Corp",
  "updatedAt": "2026-10-02T13:52:22.199883Z",
  "sections": [
    {
      "type": "OVERVIEW",
      "text": "Legend Biotech Corp is a biotechnology company focused on developing engineered CAR-T cell therapies, primarily for cancer, with pipeline research also targeting autoimmune diseases. Its commercial product is CARVYKTI (ciltacabtagene autoleucel, or cilta-cel), a treatment for certain adults with relapsed or refractory multiple myeloma, developed and commercialized in collaboration with Johnson & Johnson. [P153737068][P153737763]\n\nFounded in 2014, Legend Biotech states its mission as “In pursuit of cures.” Its operations span the United States, Europe, and China, including research and manufacturing activities in China; the company’s locations page reports more than 1,500 U.S. employees and more than 1,000 in Europe. [https://legendbiotech.com/our-story/][https://legendbiotech.com/mission-vision-values/][https://legendbiotech.com/locations/][P153737530] For the year ended December 31, 2025, it reported total revenue of $1,028.9 million, including collaboration revenue and license and other revenue. [T17729139]\n[P153737068][P153737763][https://legendbiotech.com/our-story/][https://legendbiotech.com/mission-vision-values/][https://legendbiotech.com/locations/][P153737530][T17729139][https://legendbiotech.com/our-story/][https://legendbiotech.com/mission-vision-values/][https://legendbiotech.com/locations/]",
      "updatedAt": "2026-10-02T13:52:22.199883Z"
    },
    {
      "type": "PRODUCTS",
      "text": "Legend Biotech’s commercial product is CARVYKTI® (ciltacabtagene autoleucel, or cilta-cel), an autologous BCMA-targeting CAR-T cell therapy for adults with relapsed or refractory multiple myeloma. Its CAR construct uses two llama-derived BCMA-binding domains, a 4-1BB costimulatory domain, and a CD3 zeta signaling chain. The treatment is made from a patient’s T cells, which are collected, modified and expanded before being infused back into the patient. [P153737763][P153737832][P153737167]\n\nThe company’s investigational pipeline includes LB1908, an autologous CAR-T candidate targeting CLDN18.2 for certain gastric, gastroesophageal-junction, esophageal and pancreatic cancers, and LB2102, a DLL-3-targeting autologous CAR-T candidate for extensive-stage small-cell lung cancer. Its broader pipeline includes other CAR-T, CAR-NK, gamma-delta CAR-T, autoimmune-disease and in-vivo CAR-T candidates; these are investigational, not marketed products. Legend also reports research, development and manufacturing capabilities, and its Nanjing subsidiary performs R&D services and manufactures and sells life-sciences research products. [P153737995][P153737994][P153737014][P153737068][T17729144]\n\nCARVYKTI global net trade sales were approximately $1.9 billion in FY2025 and $963 million in FY2024; these figures are not Legend’s recognized revenue. Legend shares profits from sales outside Greater China with its collaboration partner, while its share of non-Greater-China net trade sales is recorded as collaboration revenue. The sources identify CARVYKTI as its commercial product but do not provide a percentage-of-performance breakdown across multiple marketed products. [https://legendbiotech.gcs-web.com/news-releases/news-release-details/legend-biotech-reports-fourth-quarter-and-full-year-2025-results][https://legendbiotech.gcs-web.com/news-releases/news-release-details/legend-biotech-reports-fourth-quarter-and-full-year-2024-results/][P153739673]\n[P153737763][P153737832][P153737167][P153737995][P153737994][P153737014][P153737068][T17729144][P153739673][https://legendbiotech.gcs-web.com/news-releases/news-release-details/legend-biotech-reports-fourth-quarter-and-full-year-2025-results][https://legendbiotech.gcs-web.com/news-releases/news-release-details/legend-biotech-reports-fourth-quarter-and-full-year-2024-results/]",
      "updatedAt": "2026-10-02T13:52:22.199883Z"
    },
    {
      "type": "GEOGRAPHY",
      "text": "Legend Biotech’s 2025 revenue was reported by customer location. The filing lists $803.6 million attributable to the United States, $26.6 million in China license-and-other revenue, and $198.7 million in collaboration revenue outside the United States. These amounts represent approximately 78.1%, 2.6%, and 19.3% of total revenue, respectively; percentages are calculated from the reported figures. [T17729147][P153739737]\n\nThe company’s geographic footprint includes U.S. offices and facilities in Somerset and Piscataway, New Jersey, and operations in China, including Nanjing, Beijing, and Shanghai. Its Nanjing properties include office, laboratory, warehouse, and GMP manufacturing space; the filing also identifies a material portion of its China R&D operations and manufacturing facilities as being in China. [P153737758][P153739079][T17729122][P153737530]\n\nThe filing lists principal subsidiaries incorporated in the British Virgin Islands, Hong Kong, China, the United States, Ireland, and Belgium, with manufacturing, sales, or R&D activities attributed to several of these jurisdictions. At year-end 2025, non-current assets were located in the United States, China, and Europe. [T17729144][T17729148]\n[T17729147][P153739737][P153737758][P153739079][T17729122][P153737530][T17729144][T17729148]",
      "updatedAt": "2026-10-02T13:52:22.199883Z"
    },
    {
      "type": "SEGMENTS",
      "text": "Legend Biotech reports as a single operating segment rather than separately named business segments. Its chief operating decision makers review the company’s results as a whole and do not receive discrete operating-segment financial information; accordingly, the company provides no segment-level revenue or contribution percentages. [P153739731]\n\nThe company’s business focus is the development of CAR-T cell therapies, including cell-therapy candidates for cancers and autoimmune diseases. This describes its overall focus, not a separately reported segment. [P153737068]\n[P153739731][P153737068]",
      "updatedAt": "2026-10-02T13:52:22.199883Z"
    },
    {
      "type": "HISTORY",
      "text": "Legend Biotech was founded in 2014 by scientists with backgrounds in immunology and gene editing. It began research into BCMA-targeted CAR-T therapy in 2015 and initiated clinical trials in China in 2016. [https://legendbiotech.com/our-story/]\n\nIn December 2017, Legend entered a worldwide collaboration and license agreement with Janssen for developing and commercializing cilta-cel. Legend’s American depositary shares began trading on Nasdaq under the symbol LEGN on June 5, 2020. [P153739640][T17729138][P153739112]\n\nOn February 28, 2022, the U.S. FDA approved cilta-cel, marketed as CARVYKTI, for adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy. The European Commission and Japan granted approvals later that year. In 2024, the FDA and European Commission approved CARVYKTI for use earlier in the treatment course. [P153741825][P153736875][P153737763]\n\nTo expand manufacturing capacity, Legend and Janssen contracted with Novartis in 2023 for cilta-cel technology transfer, manufacturing, and supply. In October 2025, Legend agreed to manufacture and supply cilta-cel for Janssen at its Raritan, New Jersey facility. [T17729134][P153738063]\n[https://legendbiotech.com/our-story/][P153739640][T17729138][P153739112][P153741825][P153736875][P153737763][T17729134][P153738063][https://legendbiotech.com/our-story/]",
      "updatedAt": "2026-10-02T13:52:22.199883Z"
    }
  ],
  "sources": [
    {
      "id": "P153737068",
      "href": "https://app.finbar.com/go?id=P153737068",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "P153737763",
      "href": "https://app.finbar.com/go?id=P153737763",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "https://legendbiotech.com/our-story/",
      "href": "https://legendbiotech.com/our-story/",
      "label": "legendbiotech.com"
    },
    {
      "id": "https://legendbiotech.com/mission-vision-values/",
      "href": "https://legendbiotech.com/mission-vision-values/",
      "label": "legendbiotech.com"
    },
    {
      "id": "https://legendbiotech.com/locations/",
      "href": "https://legendbiotech.com/locations/",
      "label": "legendbiotech.com"
    },
    {
      "id": "P153737530",
      "href": "https://app.finbar.com/go?id=P153737530",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "T17729139",
      "href": "https://app.finbar.com/go?id=T17729139",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "P153737832",
      "href": "https://app.finbar.com/go?id=P153737832",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "P153737167",
      "href": "https://app.finbar.com/go?id=P153737167",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "P153737995",
      "href": "https://app.finbar.com/go?id=P153737995",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "P153737994",
      "href": "https://app.finbar.com/go?id=P153737994",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "P153737014",
      "href": "https://app.finbar.com/go?id=P153737014",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "T17729144",
      "href": "https://app.finbar.com/go?id=T17729144",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "https://legendbiotech.gcs-web.com/news-releases/news-release-details/legend-biotech-reports-fourth-quarter-and-full-year-2025-results",
      "href": "https://legendbiotech.gcs-web.com/news-releases/news-release-details/legend-biotech-reports-fourth-quarter-and-full-year-2025-results",
      "label": "legendbiotech.gcs-web.com"
    },
    {
      "id": "https://legendbiotech.gcs-web.com/news-releases/news-release-details/legend-biotech-reports-fourth-quarter-and-full-year-2024-results/",
      "href": "https://legendbiotech.gcs-web.com/news-releases/news-release-details/legend-biotech-reports-fourth-quarter-and-full-year-2024-results/",
      "label": "legendbiotech.gcs-web.com"
    },
    {
      "id": "P153739673",
      "href": "https://app.finbar.com/go?id=P153739673",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "T17729147",
      "href": "https://app.finbar.com/go?id=T17729147",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "P153739737",
      "href": "https://app.finbar.com/go?id=P153739737",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "P153737758",
      "href": "https://app.finbar.com/go?id=P153737758",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "P153739079",
      "href": "https://app.finbar.com/go?id=P153739079",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "T17729122",
      "href": "https://app.finbar.com/go?id=T17729122",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "T17729148",
      "href": "https://app.finbar.com/go?id=T17729148",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "P153739731",
      "href": "https://app.finbar.com/go?id=P153739731",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "P153739640",
      "href": "https://app.finbar.com/go?id=P153739640",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "T17729138",
      "href": "https://app.finbar.com/go?id=T17729138",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "P153739112",
      "href": "https://app.finbar.com/go?id=P153739112",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "P153741825",
      "href": "https://app.finbar.com/go?id=P153741825",
      "label": "Legend Biotech Corp — Full financial report (2021 Y)",
      "documentId": "D-12412b81db714954919a03b363b57862"
    },
    {
      "id": "P153736875",
      "href": "https://app.finbar.com/go?id=P153736875",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "T17729134",
      "href": "https://app.finbar.com/go?id=T17729134",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    },
    {
      "id": "P153738063",
      "href": "https://app.finbar.com/go?id=P153738063",
      "label": "Legend Biotech Corp — Full financial report (2025 Y)",
      "documentId": "D-637a51ce50f74f509348f9fd89623d15"
    }
  ]
}